Compare
PPG Industries Inc vs Ecolab Inc. vs Teva Pharmaceutical Industries Ltd vs Regeneron Pharmaceuticals, Inc.
| Latest fiscal year | PPG Industries Inc PPG | Ecolab Inc. ECL | Teva Pharmaceutical Industries Ltd TEVA | Regeneron Pharmaceuticals, Inc. REGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $15.88B | $16.08B | $17.26B | $14.34B |
| Revenue growth (YoY) | +0.2% | +2.2% | +4.3% | +1.0% |
| Gross margin | 41.3% (computed) | 44.5% (computed) | 51.8% | n/a |
| Operating margin | n/a | 17.0% | 12.5% | 24.9% |
| Net margin | 9.9% | 13.0% | 8.2% | 31.4% |
| Net income | $1.58B | $2.09B | $1.41B | $4.50B |
| EPS (Diluted) | $6.94 | $7.28 | $1.21 | $41.48 |
| Operating cash flow | $1.94B | $2.95B | $1.65B | $4.98B |
| Free cash flow | $1.16B | $1.90B | $1.15B | $4.08B |
| Cash & equivalents | $2.16B | $646.20M | $3.56B | $3.12B |
| Total assets | $22.10B | $24.70B | $40.75B | $40.56B |
| Total liabilities | $14.00B | $14.89B | $32.83B | $9.30B |
| Shareholders' equity | $8.10B | $9.80B | $7.91B | $31.26B |
| Return on year-end equity | 19.5% | 21.4% | 17.8% | 14.4% |
| Shares outstanding | 223.43M | 282.00M | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | PPG Industries Inc | Ecolab Inc. | Teva Pharmaceutical Industries Ltd | Regeneron Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $15.88B Ended 2025-12-31 | $16.08B Ended 2025-12-31 | $17.26B Ended 2025-12-31 | $14.34B Ended 2025-12-31 |
| 1 year earlier | $15.85B Ended 2024-12-31 | $15.74B Ended 2024-12-31 | $16.54B Ended 2024-12-31 | $14.20B Ended 2024-12-31 |
| 2 years earlier | $16.24B Ended 2023-12-31 | $15.32B Ended 2023-12-31 | $15.85B Ended 2023-12-31 | $13.12B Ended 2023-12-31 |
| 3 years earlier | $15.61B Ended 2022-12-31 | $14.19B Ended 2022-12-31 | $14.93B Ended 2022-12-31 | $12.17B Ended 2022-12-31 |
| 4 years earlier | $16.80B Ended 2021-12-31 | $12.73B Ended 2021-12-31 | $15.88B Ended 2021-12-31 | $16.07B Ended 2021-12-31 |